Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

By L. Corrales, L. Glickman, S. McWhirter, D. Kanne, Kelsey E Sivick, George E. Katibah, Seng-Ryong Woo, E. Lemmens, Tamara Banda, Justin J. Leong and 3 more. 2015

1,351 citations recorded by the source corpus.

Spontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident dendritic cells. Based on recent observations indicating that IFN-β expression was dependent upon activation of the host STING pathway, we hypothesized that direct engagement of STING through intratumoral administration of specific agonists would result in effective antitumor therapy. After proof-of-principle studies using the mouse STING agonist DMXAA showed a potent therapeutic effect, we generated synthetic cyclic dinucleotide (CDN) derivatives that activated all human STING alleles as well as murine STING. Intratumoral injection of STING agonists induced profound regression of established tumors in mice and generated substantial systemic immune responses capable of rejecting distant metastases and providing long-lived immunologic memory. Synthetic CDNs have high translational potential as a cancer therapeutic.

Subfields: Immunology, Infectious Diseases, Computational Biology & Bioinformatics, Medical & Health AI

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

  1. Tuo Li
  2. D. Munn
  3. A. Mellor
  4. Zhijian J. Chen
  5. D. Irvine
  6. S. Spranger
  7. Shizuo Akira
  8. N. Perkins

In Infectious Diseases

  1. Tuo Li
  2. Zhijian J. Chen
  3. A. Mellor
  4. D. Irvine
  5. D. Munn

Citations in the corpus